Literature DB >> 17561131

Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients.

Stephen D W Beck1, Matthew D Peterson, Richard Bihrle, John P Donohue, Richard S Foster.   

Abstract

PURPOSE: We defined the blood loss, operative time and short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary series to assess whether laparoscopic retroperitoneal lymph node dissection actually confers the magnitude of benefit claimed.
MATERIALS AND METHODS: A retrospective chart review was performed of 75 consecutive patients who underwent primary retroperitoneal lymph node dissection during the 18 months ending May 2005. Two patients were excluded, including 1 who underwent right hemicolectomy for cecal adenocarcinoma and 1 with a pure seminomatous intra-abdominal testicle.
RESULTS: Of the 73 patients 69 (94%) underwent unilateral dissection and 60 (82.2%) underwent a nerve sparing procedure. Mean operative time was 132 minutes (range 81 to 246) and mean blood loss was 207 cc (range 50 to 500). Nasogastric tubes were placed in 2 patients (2.7%). Mean time to start clear liquids was 1.0 day. Mean hospital stay was 2.8 days (range 2 to 4).
CONCLUSIONS: The short-term morbidity of open retroperitoneal lymph node dissection, including operative time, blood loss and hospital stay, has significantly improved compared to historical controls. Perioperative management has changed with time. Comparing the morbidity of laparoscopic retroperitoneal lymph node dissection to that of historical controls is inappropriate.

Entities:  

Mesh:

Year:  2007        PMID: 17561131     DOI: 10.1016/j.juro.2007.03.123

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Testicular cancer: Decision tree model has potential to improve NSGCT management.

Authors:  Ornob P Roy; Louis R Kavoussi
Journal:  Nat Rev Urol       Date:  2010-06       Impact factor: 14.432

2.  [Comments on retroperitoneal lymphadenectomy - laparoscopic versus robotic].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

Review 3.  Robot-assisted laparoscopic retroperitoneal lymph node dissection: a minimally invasive surgical approach for testicular cancer.

Authors:  Harsha R Mittakanti; James R Porter
Journal:  Transl Androl Urol       Date:  2020-01

4.  Management options for stage 1 nonseminomatous germ cell tumors of the testis.

Authors:  Stephen D W Beck
Journal:  Indian J Urol       Date:  2010 Jan-Mar

5.  Clinical outcomes in patients with stage I non-seminomatous germ cell cancer.

Authors:  Zhao-Jie Lv; Song Wu; Pei Dong; Kai Yao; Yin-Yin He; Yao-Ting Gui; Fang-Jian Zhou; Zhuo-Wei Liu; Zhi-Ming Cai
Journal:  Asian J Androl       Date:  2013-05-20       Impact factor: 3.285

Review 6.  Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer.

Authors:  Patrick A Kenney; Ingolf A Tuerk
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

7.  Current update of management of clinical stage I non seminomatous germ cell tumors of testis.

Authors:  T B Yuvaraja
Journal:  Indian J Surg Oncol       Date:  2012-03-20

8.  Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes.

Authors:  Nicholas R Rocco; Sean P Stroup; Haidar M Abdul-Muhsin; Michael T Marshall; Michael G Santomauro; Matthew S Christman; James O L'Esperance; Erik P Castle
Journal:  World J Urol       Date:  2019-09-09       Impact factor: 4.226

Review 9.  A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer.

Authors:  Zeyad R Schwen; Mohit Gupta; Phillip M Pierorazio
Journal:  Adv Urol       Date:  2018-05-03

Review 10.  Optimal management of testicular cancer: from self-examination to treatment of advanced disease.

Authors:  Stephen Dw Beck
Journal:  Open Access J Urol       Date:  2010-08-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.